Kenshi Suzuki

Summary

Country: Japan

Publications

  1. doi request reprint Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo Shibuya ku, Tokyo, 150 8935, Japan
    Int J Hematol . 2016
  2. doi request reprint Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Hiroo 4 1 22 Shibuya ku, Tokyo, 1508935, Japan
    Int J Hematol 101:286-94. 2015
  3. doi request reprint Current therapeutic strategy for multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Jpn J Clin Oncol 43:116-24. 2013
  4. pmc Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo 150 8935, Japan
    Clin Exp Nephrol 16:659-71. 2012
  5. doi request reprint Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma
    Klio Konstantinou
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 144:696-704. 2009
  6. doi request reprint Follicular lymphoma with marked infiltration of eosinophils
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Tokyo, Japan
    Pathol Int 58:701-5. 2008
  7. ncbi request reprint IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Am J Hematol 81:824-31. 2006
  8. doi request reprint High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases
    Nobuhiro Tsukada
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo, 150 8935, Japan
    Int J Hematol 103:299-305. 2016
  9. ncbi request reprint Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22, Hiroo, Shibuya, Tokyo, 150 8935, Japan
    Eur J Drug Metab Pharmacokinet 33:191-8. 2008
  10. doi request reprint [The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma]
    Junko Inoue
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 56:2311-7. 2015

Collaborators

Detail Information

Publications36

  1. doi request reprint Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo Shibuya ku, Tokyo, 150 8935, Japan
    Int J Hematol . 2016
    ..Of 13 response-evaluable patients, one achieved a partial response (duration ∼38 weeks; ixazomib cohort) and seven had stable disease...
  2. doi request reprint Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Hiroo 4 1 22 Shibuya ku, Tokyo, 1508935, Japan
    Int J Hematol 101:286-94. 2015
    ..In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412...
  3. doi request reprint Current therapeutic strategy for multiple myeloma
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Jpn J Clin Oncol 43:116-24. 2013
    ..However, multiple myelomas are still difficult to cure and require long-term disease control. In recent years, the introduction of novel drugs (bortezomib, lenalidomide and thalidomide) has improved treatment...
  4. pmc Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo 150 8935, Japan
    Clin Exp Nephrol 16:659-71. 2012
    ..However, they are still difficult to be cured and require long-term disease control. In recent years, introduction of novel agents has changed their treatment strategies from the palliation therapy to the clinical cure...
  5. doi request reprint Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma
    Klio Konstantinou
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 144:696-704. 2009
    ....
  6. doi request reprint Follicular lymphoma with marked infiltration of eosinophils
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Tokyo, Japan
    Pathol Int 58:701-5. 2008
    ..This was a unique case of follicular lymphoma with extensive eosinophil infiltration, and to the best of the authors' knowledge this is the first such case ever reported...
  7. ncbi request reprint IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Am J Hematol 81:824-31. 2006
    ..These findings indicate that IAP family proteins might play a role in worsening the prognosis of MM patients in association with chemotherapy-induced overexpression of MDR1 or LRP...
  8. doi request reprint High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases
    Nobuhiro Tsukada
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo, 150 8935, Japan
    Int J Hematol 103:299-305. 2016
    ..It is also important to develop additional treatment for patients who do not achieve a hematological and/or organ response...
  9. ncbi request reprint Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22, Hiroo, Shibuya, Tokyo, 150 8935, Japan
    Eur J Drug Metab Pharmacokinet 33:191-8. 2008
    ..These results suggest that MCFG can be administered safely to patients with liver or kidney dysfunction without adjusting the dose...
  10. doi request reprint [The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma]
    Junko Inoue
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 56:2311-7. 2015
    ..However, if treatment does not produce a reincrease in CD138⁺ levels, long term survival might be difficult to achieve...
  11. ncbi request reprint [Primary systemic AL amyloidosis with remarkable calcification in the spleen]
    Kiyotaka Uchiyama
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 55:334-9. 2014
    ..The platelet count rose with an improvement in hepatic congestion due to reinforced fluid removal during dialysis. ..
  12. ncbi request reprint [Clinical analysis of autologous stem cell transplantation for nine cases of cardiac amyloidosis]
    Mizuki Ogura
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 53:710-5. 2012
    ..Further studies are required to clarify an effective MEL dose and to refine selection criteria for patients undergoing HDM/SCT...
  13. pmc A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Takashi Watanabe
    Department of Haematology, National Cancer Centre Hospital, Tokyo, Japan
    Br J Haematol 172:745-56. 2016
    ..The dose was efficacious and tolerable in heavily pre-treated Japanese patients; however, meticulous control of hypertension may be necessary for further carfilzomib use...
  14. ncbi request reprint Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection
    Yasunori Honda
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 55:570-2. 2014
    ..The diameter of the hyperpigmentation area was 8 cm. To reduce the severity of this reaction, we used an air sandwich technique, and succeeded in ameliorating the skin changes. ..
  15. doi request reprint Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma
    Yu Abe
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Exp Hematol 37:956-68. 2009
    ....
  16. ncbi request reprint Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia
    Tamara Keith
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
    Br J Haematol 137:206-15. 2007
    ..These findings indicate that the bone marrow microenvironment in MDS --> OL and de novo AML differs remarkably, suggesting the different efficacy of anti-angiogenic therapy between de novo AML and leukaemia secondary to MDS...
  17. pmc Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan
    Kenshi Suzuki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Cancer Sci . 2017
    ..Carfilzomib pharmacokinetics were not affected by lenalidomide and dexamethasone. The KRd regimen was well tolerated and showed efficacy in Japanese RRMM patients. This article is protected by copyright. All rights reserved...
  18. doi request reprint Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis
    Chihiro Shimazaki
    Department of Hematology, Japan Community Healthcare Organization, Kyoto Kuramaguchi Medical Center, Kyoto, Japan
    Int J Hematol 103:79-85. 2016
    ..Peripheral neuropathy was the most common non-hematologic toxicity (16%). We demonstrated that BMD is safe and tolerable for Japanese AL patients without severe cardiac damage...
  19. doi request reprint Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study
    Yasunori Nakagawa
    Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    J Infect Chemother 17:58-67. 2011
    ..BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases...
  20. ncbi request reprint Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia
    Airi Hamano
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 55:428-35. 2014
    ..However, a higher dose of melphalan was observed to have been used in patients who had CAs. Longer follow-up periods are necessary for an accurate risk assessment. ..
  21. ncbi request reprint [Increased level of KL-6 in a BJP-λ-type multiple myeloma patient with poor prognosis]
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Japan
    Rinsho Ketsueki 53:521-5. 2012
    ..For this patient, multiple myeloma with high KL-6 was refractory to chemotherapy, suggesting that new treatment strategies, including transplantation of hematopoietic stem cells, are required...
  22. doi request reprint Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma
    Thomas J Smith
    Department of Comprehensive Pathology, Ageing and Developmental Sciences, Graduate School, Tokyo Medical and Dental University, 1 5 45 Bunkyo Ku, Tokyo, Japan
    Exp Mol Pathol 89:284-90. 2010
    ..TLR expression is highly variable among lymphoma subtypes. However, despite this some significant differences exist that may prove useful in the development of novel therapeutic strategies...
  23. ncbi request reprint Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis
    Kanji Miyazaki
    a Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Amyloid 23:221-224. 2016
    ..002 and 0.002, respectively) and in patients undergoing treatment (p = 0.031 and 0.016, respectively). CE/IS is an acceptable alternative to IFE...
  24. ncbi request reprint [Close correlations between CD20 expression, a small mature plasma cell morphology and t(11 ; 14) in multiple myeloma]
    Isao Matsuda
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 46:1293-7. 2005
    ..Two color analysis of CD38 x CD20 antigens may be necessary to investigate CD20 expression on MM cells. Rituximab may be effective for the treatment of CD20-positive MM...
  25. doi request reprint Type AB thymoma accompanied by pure red cell aplasia and Good syndrome with CMV infection of tumor cells
    Junichi Shiraishi
    Department of Pathology, Japanese Red Cross Medical Center, Shibuya ku, Tokyo, Japan
    Pathol Int 58:489-93. 2008
    ..Several cases of Good syndrome with widespread CMV infection have been reported, but it is extremely rare for CMV-inclusion bodies to be found in tumor cells. No thymoma cases involving CMV infection of tumor cells have been reported...
  26. pmc Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
    Kenshi Suzuki
    Japanese Red Cross Medical Center, Tokyo, Japan
    Cancer Sci 107:653-8. 2016
    ..The efficacy and safety of Rd were consistent with data from larger studies, including the FIRST trial, thereby supporting the use of Rd continuous in Japanese patients with NDMM who are ineligible for stem cell transplantation. ..
  27. ncbi request reprint Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis
    Sohsuke Meshitsuka
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Int J Hematol . 2016
    ....
  28. doi request reprint Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy
    Yasunori Nakagawa
    Department of Oncology and Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo, 150 8935, Japan
    J Infect Chemother 15:174-9. 2009
    ..At the onset of FN, they were expressed in points for evaluation. Further prospective studies are needed to determine whether these risk factors are suitable for use in actual cases...
  29. ncbi request reprint Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL)
    Yasunori Nakagawa
    Department of Comprehensive Pathology, Aging and Developmental Sciences, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan
    Am J Hematol 78:173-80. 2005
    ..05), NAIP (P <0.05), and XIAP (P <0.05). These findings suggest that higher expression of various IAPs is associated with the chemotherapy-resistant nature of this specific type of leukemia...
  30. ncbi request reprint Plasma concentration of micafungin in patients with hematologic malignancies
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    J Infect Chemother 13:39-45. 2007
    ....
  31. pmc Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma
    Takashi Watanabe
    Hematology Division, National Cancer Center Hospital, Tokyo, Japan
    PLoS ONE 10:e0128662. 2015
    ..Thus, pretreatment LPS-CXCL10 mRNA and/or the six combinations may serve as potential biomarkers for the response to bortezomib treatment in MM patients. ..
  32. doi request reprint Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry
    Kanji Miyazaki
    Department of Hematology, Japanese Red Cross Medical Center, 4 1 22 Hiroo, Shibuya ku, Tokyo, 150 8935, Japan
    Int J Hematol 102:289-95. 2015
    ..7 % of cases, and hence these analyses appear to be valuable in diagnosing the type of amyloidosis...
  33. doi request reprint [Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation]
    Sohsuke Meshitsuka
    Department of Hematology, Japanese Red Cross Medical Center
    Rinsho Ketsueki 56:699-704. 2015
    ..This case raises the possibility of a new strategy for refractory Hodgkin lymphoma showing residual lesions after auto-PBSCT. ..
  34. doi request reprint Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: a rare case
    Kanji Miyazaki
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Acta Haematol 132:68-72. 2014
    ..We present a case of CMML with dmin and unusual intracytoplasmic crystalline inclusions. To our knowledge, no such case has previously been reported...
  35. ncbi request reprint [Therapy of non-Hodgkin's lymphoma]
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center
    Nihon Rinsho 65:521-8. 2007
  36. ncbi request reprint Clinical implications of abnormalities of chromosomes 1 and 13 in multiple myeloma
    Yasunori Nakagawa
    Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
    Acta Haematol 109:129-36. 2003
    ..02). Consequently, aggressive treatment such as early stem cell transplantation and so on is needed to improve their survival...